PL366070A1 - Sposób radioterapii - Google Patents

Sposób radioterapii

Info

Publication number
PL366070A1
PL366070A1 PL01366070A PL36607001A PL366070A1 PL 366070 A1 PL366070 A1 PL 366070A1 PL 01366070 A PL01366070 A PL 01366070A PL 36607001 A PL36607001 A PL 36607001A PL 366070 A1 PL366070 A1 PL 366070A1
Authority
PL
Poland
Prior art keywords
bone
tumors
human
subject
treatment
Prior art date
Application number
PL01366070A
Other languages
English (en)
Other versions
PL206209B1 (pl
Inventor
Roy H. Larsen
Gjermund Henriksen
Original Assignee
Anticancer Therapeutic Inventions As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Therapeutic Inventions As filed Critical Anticancer Therapeutic Inventions As
Publication of PL366070A1 publication Critical patent/PL366070A1/pl
Publication of PL206209B1 publication Critical patent/PL206209B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
PL366070A 2000-07-04 2001-07-04 Zastosowanie emitującego cząstki alfa radionuklidu aktynu albo toru lub jego kompleksu skierowanego docelowo do kości, kompozycja radiofarmaceutyczna, skierowany docelowo do kości kompleks radionuklidu i jego zastosowanie w medycynie oraz zestaw do leczenia powierzchni kości albo nowotworów kośćca PL206209B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20003457A NO313180B1 (no) 2000-07-04 2000-07-04 Bensökende alfapartikkel emitterende radiofarmasöytika

Publications (2)

Publication Number Publication Date
PL366070A1 true PL366070A1 (pl) 2005-01-24
PL206209B1 PL206209B1 (pl) 2010-07-30

Family

ID=19911348

Family Applications (1)

Application Number Title Priority Date Filing Date
PL366070A PL206209B1 (pl) 2000-07-04 2001-07-04 Zastosowanie emitującego cząstki alfa radionuklidu aktynu albo toru lub jego kompleksu skierowanego docelowo do kości, kompozycja radiofarmaceutyczna, skierowany docelowo do kości kompleks radionuklidu i jego zastosowanie w medycynie oraz zestaw do leczenia powierzchni kości albo nowotworów kośćca

Country Status (15)

Country Link
US (2) US7056275B2 (pl)
EP (1) EP1296722B1 (pl)
JP (1) JP5219325B2 (pl)
KR (1) KR100892002B1 (pl)
AT (1) ATE305313T1 (pl)
AU (2) AU6773401A (pl)
CA (1) CA2413736C (pl)
CZ (1) CZ299087B6 (pl)
DE (1) DE60113683T2 (pl)
DK (1) DK1296722T3 (pl)
EA (1) EA004899B1 (pl)
ES (1) ES2250419T3 (pl)
NO (1) NO313180B1 (pl)
PL (1) PL206209B1 (pl)
WO (1) WO2002005859A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
AU4906901A (en) * 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
CA2522148C (en) * 2003-04-15 2010-07-13 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
EA020542B1 (ru) * 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
EP1763372B1 (en) * 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuclides for medical use
LU91085B1 (en) * 2004-06-25 2005-12-27 European Community Radionuclides for medical use.
US7794691B2 (en) 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
FR2913970B1 (fr) * 2007-03-19 2009-06-12 Cogema Production de thorium 228 a partir d'un sel de thorium naturel
US20080249398A1 (en) * 2007-04-09 2008-10-09 Harder George Fred Hybrid Source Containing Multi-Radionuclides for Use in Radiation Therapy
WO2011025790A1 (en) 2009-08-24 2011-03-03 Lumiphore, Inc. Macrocyclic hopo chelators
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
US9202602B2 (en) * 2010-02-10 2015-12-01 Uchicago Argonne, Llc Production of isotopes using high power proton beams
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
GB201600161D0 (en) 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
EP3432936A1 (en) 2016-03-24 2019-01-30 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
CR20180581A (es) 2016-06-10 2019-02-11 Bayer Pharma AG Complejos radio-farmacéuticos
SG11201910176PA (en) 2017-05-11 2019-11-28 Alpha Tau Medical Ltd Polymer coatings for brachytherapy devices
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
FR3088769B1 (fr) 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
WO2020180756A1 (en) * 2019-03-01 2020-09-10 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
PH12022551370A1 (en) 2019-12-05 2023-05-08 Sciencons AS Production of highly purified 212pb
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата
IL303002B1 (en) 2020-12-16 2026-08-01 Alpha Tau Medical Ltd Radiation therapy using scattered alpha emitters with enhanced beta therapy
KR102545315B1 (ko) 2021-01-05 2023-06-20 한국과학기술원 의료용 방사성 동위원소의 생산 방법 및 시스템

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2329147A (en) * 1938-05-07 1943-09-07 Rare Chemicals Inc Stabilized metal sol and method of preparing same
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5192526A (en) * 1989-05-02 1993-03-09 Mallinckrodt Medical, Inc. Kit for preparation of rhenium therapeutic agents for bone cancer without purification
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
WO2000076556A2 (en) * 1999-06-11 2000-12-21 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy

Also Published As

Publication number Publication date
US7335154B2 (en) 2008-02-26
JP2004503331A (ja) 2004-02-05
KR100892002B1 (ko) 2009-04-07
CZ299087B6 (cs) 2008-04-23
PL206209B1 (pl) 2010-07-30
WO2002005859A2 (en) 2002-01-24
KR20030029100A (ko) 2003-04-11
ATE305313T1 (de) 2005-10-15
DE60113683T2 (de) 2006-07-06
NO20003457L (no) 2002-01-07
EP1296722A2 (en) 2003-04-02
US7056275B2 (en) 2006-06-06
DE60113683D1 (en) 2006-02-09
EP1296722B1 (en) 2005-09-28
AU6773401A (en) 2002-01-30
NO20003457D0 (no) 2000-07-04
EA004899B1 (ru) 2004-08-26
US20030166989A1 (en) 2003-09-04
CA2413736C (en) 2009-08-18
US20060135842A1 (en) 2006-06-22
DK1296722T3 (da) 2006-02-13
AU2001267734B2 (en) 2005-09-01
EA200201258A1 (ru) 2003-06-26
WO2002005859A3 (en) 2002-09-06
CA2413736A1 (en) 2002-01-24
NO313180B1 (no) 2002-08-26
ES2250419T3 (es) 2006-04-16
JP5219325B2 (ja) 2013-06-26

Similar Documents

Publication Publication Date Title
DE60113683D1 (en) Radiotherapy
TR200102707T2 (tr) AĞrì hafifletme, kemik kanseri terapisi ve kemik yzeyinin saĞlìklì tutulmasì i‡in kire‡lenmiç hedef dokulara y”nelik radyum-223 hazìrlanmasì ve kullanìmì.
Nag et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
D D’Souza et al. Is the α/β ratio for prostate cancer low?
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
DE60225702D1 (de) Strontium verbindung zur behandlung von sub-dermalem weichteilschmerz
ATE262909T1 (de) Intravenöse alendronatformulierungen
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
AU3842989A (en) Conjugates for bone imaging and bone cancer therapy
DE69434244D1 (de) Verbesserte krebstherapie
WO2005023367A3 (en) X-ray and gamma ray emitting temporary high dose rate brachyterapy source
PL1750596T3 (pl) Element łączący do wprowadzania do środka struktury kostnej ciała człowieka lub zwierzęcia i związany z nim system lokalizujący
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
PL367707A1 (pl) Kompozycja farmaceutyczna stosowana w leczeniu nowotworów złośliwych zawierająca kombinację bisfosfonianu, inhibitora COX-2 i taksolu
Ng et al. Customized conformal high-dose-rate brachytherapy boost for limited-volume nasopharyngeal cancer
Iwamoto et al. Radiation therapy for prostate cancer
GB0403856D0 (en) Composition
UA11383U (uk) Спосіб терапії хворих на рак щитовидної залози з множинними метастазами в скелет
Kim et al. Spine Metastases as the Initial Sign of Differentiated Thyroid Carcinoma: Two Case Reports
IT1312106B1 (it) Suola o soletta per calzature,particolarmente per la terapia del corpo umano mediante campi magnetici
CO5150237A1 (es) Metodos de aumentar el volumen oseo que comprenden la administracion de un agonista fp selectivo que no ocurre naturalmente y un compuesto de antiresorcion a un sujeto que requiere tal tratamiento

Legal Events

Date Code Title Description
RECP Rectifications of patent specification